Zelboraf 2017 U.S. PROMOTIONAL AUDIT REPORT

Zelboraf 2017 U.S. PROMOTIONAL AUDIT REPORT

  • July 2018 •
  • 24 pages •
  • Report ID: 5210760 •
  • Format: PDF
The 5 Key Questions Addressed by this Report:
• How many physicians were reached by Zelboraf through reportable promotional activity in 2017 and how does this compare to its peer set in the Erdheun-Chester Disease and Melanoma markets?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Daiichi Sankyo and Genentech’s depth of coverage vary within key specialties (e.g., Hematology/Oncology, Medical Oncology, Dermatology, and Internal Medicine) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Zelboraf throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most frequent meal recipients and top paid speakers for Zelboraf in 2017?

Data Sources and Methodology:
• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. More than four years of longitudinal data is available – covering payments to more than 975,000 U.S. healthcare professionals.
• Over 1,900 paid interactions across 1,100 physicians made on behalf of Zelboraf were carefully examined to support our analysis. In addition, interaction data from 7 peer products (e.g. Cotellic, Imlygic, Keytruda, Mekinist, Opdivo, Proleukin, and Tafinlar ) was leveraged to provide benchmarking and market insights.